| scholarly article | Q13442814 |
| P50 | author | Katy Jeannot | Q61011948 |
| P2093 | author name string | D Fournier | |
| M Berrazeg | |||
| P Plésiat | |||
| Véronique Yvette Ntsogo Enguéné | |||
| I Broutin | |||
| S Loeffert | |||
| P2860 | cites work | Detection of clonally related Escherichia coli isolates producing different CMY β-lactamases from a cystic fibrosis patient | Q44942628 |
| Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. | Q46918548 | ||
| Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). | Q47570250 | ||
| Contribution of asparagine 346 residue to the carbapenemase activity of CMY-2 β-lactamase | Q50911138 | ||
| Pseudomonas aeruginosa isolates with modified beta-lactamase inducibility: effects on beta-lactam sensitivity | Q54516014 | ||
| Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa | Q61833650 | ||
| Genetic recombination in Pseudomonas aeruginosa | Q73881599 | ||
| Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem | Q27658832 | ||
| Avibactam and Class C -Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance | Q27684678 | ||
| Common Virulence Factors for Bacterial Pathogenicity in Plants and Animals | Q28292772 | ||
| Construction of improved Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa | Q29615291 | ||
| Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein | Q33422951 | ||
| In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters | Q34134689 | ||
| Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance | Q34163308 | ||
| Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. | Q34393008 | ||
| High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. | Q34508854 | ||
| Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study | Q34932869 | ||
| Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms | Q35007624 | ||
| Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase | Q35014136 | ||
| Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels | Q35326845 | ||
| Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections | Q36095065 | ||
| Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation | Q36295397 | ||
| AmpC beta-lactamases | Q37366249 | ||
| Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance | Q37794342 | ||
| Interplay between chromosomal beta-lactamase and the MexAB-OprM efflux system in intrinsic resistance to beta-lactams in Pseudomonas aeruginosa | Q39469881 | ||
| Genotypic and phenotypic variation in Pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections | Q39656697 | ||
| Aminoglycoside efflux in Pseudomonas aeruginosa: involvement of novel outer membrane proteins. | Q39731858 | ||
| Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. | Q40625683 | ||
| Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC | Q41075944 | ||
| Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. | Q41183478 | ||
| Carbapenem resistance in cystic fibrosis strains of Pseudomonas aeruginosa as a result of amino acid substitutions in porin OprD. | Q41452848 | ||
| Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals | Q41757275 | ||
| Population structure and antimicrobial susceptibility of both nonpersistent and persistent Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients | Q41822095 | ||
| Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients | Q41839265 | ||
| Cephalosporinase and penicillinase activities of a β-lactamase from Pseudomonas pyocyanea | Q41918427 | ||
| Resistance of Pseudomonas aeruginosa mutants with altered control of chromosomal beta-lactamase to piperacillin, ceftazidime, and cefsulodin | Q42115498 | ||
| Emergence of a mutL mutation causing multilocus sequence typing-pulsed-field gel electrophoresis discrepancy among Pseudomonas aeruginosa isolates from a cystic fibrosis patient. | Q42152337 | ||
| Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa | Q42612014 | ||
| Differential beta-lactam resistance response driven by ampD or dacB (PBP4) inactivation in genetically diverse Pseudomonas aeruginosa strains | Q43077051 | ||
| Extended-spectrum cephalosporinases in Pseudomonas aeruginosa | Q43128351 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Pseudomonas aeruginosa | Q31856 |
| P304 | page(s) | 6248-6255 | |
| P577 | publication date | 2015-07-27 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins | |
| P478 | volume | 59 |
| Q47218700 | Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms. |
| Q38777049 | Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles |
| Q59126430 | Association between possession of ExoU and antibiotic resistance in Pseudomonas aeruginosa |
| Q47748447 | Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. |
| Q53824657 | Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections. |
| Q60303457 | Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa |
| Q95831914 | Digital multiplex ligation assay for highly multiplexed screening of β-lactamase-encoding genes in bacterial isolates |
| Q46286684 | Diversity and regulation of intrinsic β-lactamases from non-fermenting and other Gram-negative opportunistic pathogens. |
| Q59811303 | Draft Genome Sequences of Two Pseudomonas aeruginosa Multidrug-Resistant Clinical Isolates, PAL0.1 and PAL1.1 |
| Q89899478 | Epidemiology of β-Lactamase-Producing Pathogens |
| Q90028088 | Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar |
| Q38741337 | Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates. |
| Q45897898 | Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Pseudomonas aeruginosa |
| Q57789664 | Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients |
| Q55456610 | Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess. |
| Q91720690 | Genomic Analysis Identifies Novel Pseudomonas aeruginosa Resistance Genes under Selection during Inhaled Aztreonam Therapy In Vivo |
| Q40056971 | Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain. |
| Q38856197 | Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections |
| Q89766030 | Hypermutator Pseudomonas aeruginosa exploits multiple genetic pathways to develop multidrug resistance during long-term infections in the airways of cystic fibrosis patients |
| Q63438192 | Identifying and exploiting genes that potentiate the evolution of antibiotic resistance |
| Q47769606 | In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa |
| Q40148490 | In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. |
| Q88031346 | Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam |
| Q57158084 | Interplay between Peptidoglycan Biology and Virulence in Gram-Negative Pathogens |
| Q49921578 | Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. |
| Q26747150 | New β-Lactamase Inhibitors in the Clinic |
| Q38862139 | Overcoming β-lactam resistance in Gram-negative pathogens |
| Q64089404 | Proteome profiling of Pseudomonas aeruginosa PAO1 identifies novel responders to copper stress |
| Q37643058 | Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence |
| Q61455281 | Resistance to Ceftolozane/Tazobactam in Arising by AmpC- and Non-AmpC-Mediated Pathways |
| Q60301100 | Risk factors and prognosis of complicated urinary tract infections caused by in hospitalized patients: a retrospective multicenter cohort study |
| Q90029135 | Stochastic Gene Expression Influences the Selection of Antibiotic Resistance Mutations |
| Q56835140 | Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014-2015 |
| Q52313185 | The Versatile Mutational Resistome of Pseudomonas aeruginosa. |
| Q89997000 | The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections |
| Q89965183 | The β-Lactamase Inhibitor Boronic Acid Derivative SM23 as a New Anti-Pseudomonas aeruginosa Biofilm |
| Q92216886 | VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa |
| Q40296000 | WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones |
| Q39120027 | What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles |
| Q52568071 | Whole-Genome Analysis of an Extensively Drug-Resistance Empedobacter falsenii Strain Reveals Distinct Features and the Presence of a Novel Metallo-ß-Lactamase (EBR-2). |
Search more.